首页 › 基金 › SymBiosis Capital Partners, LLC › EVMN
SymBiosis Capital Partners, LLC 对 EVMN 的持仓历史
EVOMMUNE INC · 医疗保健
SymBiosis Capital Partners, LLC 在 Q1 2026 的 13F 申报中披露持有 EVMN(EVOMMUNE INC)1,280,778 股,市值约 US$29.4M,约占其申报组合的 55.80%,在其申报持仓中市值排名第 1 位。 SymBiosis Capital Partners, LLC 最近 2 个申报季度中有 2 个季度披露了 EVMN 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-18 · 来源: SEC EDGAR Form 13F-HR
SymBiosis Capital Partners, LLC 对 EVMN 的持仓演变
SymBiosis Capital Partners, LLC 于 Q4 2025 首次披露 EVMN 持仓:1,280,778 股(约 US$21.9M)。 该持仓在 Q1 2026 达到峰值 1,280,778 股,市值约 US$29.4M。 在 2 次申报中,SymBiosis Capital Partners, LLC 的持股数量始终未变。 最近一期申报(Q1 2026)显示持股 1,280,778 股、市值约 US$29.4M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 1.28M | $21.93M | 新进 |
| Q1 2026 | 1.28M | $29.45M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 EVMN 与 13F 数据
EVMN(EVOMMUNE INC)属于医疗保健行业。我们追踪的基金中还有 116 只申报持有 EVMN,申报仓位最大的包括:EQT Fund Management S.a r.l. (US$70.3M), RA CAPITAL MANAGEMENT, L.P. (US$46.4M), Pivotal bioVenture Partners Investment Advisor LLC (US$25.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 EVMN 的基金
- EQT Fund Management S.a r.l. 5.29M 股 · $70.28M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 3.49M 股 · $46.44M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.93M 股 · $25.61M · Q2 2026
- Nan Fung Group Holdings Ltd 1.44M 股 · $19.15M · Q2 2026
- Defilade Capital Management, L.P. 793.14K 股 · $10.54M · Q2 2026
- Velan Capital Investment Management LP 451.25K 股 · $6.00M · Q2 2026
- GREAT POINT PARTNERS LLC 325.00K 股 · $4.32M · Q2 2026
- Blue Owl Capital Holdings LP 180.00K 股 · $2.39M · Q2 2026
- NEXTBio Capital Management LP 119.06K 股 · $1.58M · Q2 2026
- Avidity Partners Management LP 75.00K 股 · $996.75K · Q2 2026
- Andera Partners 97.36K 股 · $804.21K · Q3 2026
更多关于 SymBiosis Capital Partners, LLC
常见问题
How long has SymBiosis Capital Partners, LLC held EVMN?
SymBiosis Capital Partners, LLC has disclosed EVMN holdings in 2 of the last 2 reported quarters, going back to Q4 2025.
What is SymBiosis Capital Partners, LLC's current position in EVMN?
As of Q1 2026, SymBiosis Capital Partners, LLC holds 1.28M shares of EVMN (EVOMMUNE INC), valued at $29.45M, representing 55.80% of its reported portfolio and ranking #1.
Has SymBiosis Capital Partners, LLC been buying or selling EVMN?
In the latest 13F filing (Q1 2026), SymBiosis Capital Partners, LLC held unchanged its position in EVMN. The position peaked in Q1 2026 at 1.28M shares.
Which other funds hold EVMN?
Other major institutional holders of EVMN include EQT Fund Management S.a r.l., RA CAPITAL MANAGEMENT, L.P., Pivotal bioVenture Partners Investment Advisor LLC, among 116 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.